

## **IN THE CLAIMS**

On page 13 of the copy of the publication, the amendments to the listing of claims serves to replace prior versions of claims from its related international application.

### **Listing of claims**

1. Triiodothyronine sulfate for use as a medicament.
2. Triiodothyronine sulphate for use as a medicament according to claim 1, having thyromimetic activity.
3. Triiodothyronine sulfate according to claim 2, for use in the treatment of pathologies due to organic deficiency of triiodothyronine.
4. Triiodothyronine sulfate according to claim 3, wherein said pathologies comprise original hypothyroidism from autoimmune thyroid affections, hormonal production defects, thyroidectomy, congenital hypothyroidism.
5. Triiodothyronine sulfate according to claim 2, for use in the treatment of disorders due to reduced activity of type I 5'-iodothyronine monodeiodinase.
6. Triiodothyronine sulfate according to claim 5, wherein said reduced activity of type I 5'-iodothyronine monodeiodinase comprises, among its grounds, hypothyroidism, non thyroidal systemic illnesses, fast, selenium shortage.
7. Pharmaceutical compositions comprising triiodothyronine sulfate as an active principle.
8. Pharmaceutical compositions according to claim 7, wherein said triiodothyronine sulfate is formulated in association with thyroxine.
9. (currently amended) Pharmaceutical compositions according to any one of claims 7 and or 8, wherein said compositions further comprise additives like excipients, diluents, dissolvents, solvents, carriers, dyestuffs, flavourings, sweeteners.
10. Pharmaceutical compositions according to claim 7, wherein triiodothyronine sulfate is administered at doses raging from 5 to 1000 µg.
11. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses raging from 10 to 500 µg.
12. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses raging from 25 to 250 µg.
13. Pharmaceutical compositions according to claim 8, wherein said association is

administered at doses ranging from 10 to 500 µg of triiodothyronine sulfate and from 10 to 250 µg of thyroxine.

14. Pharmaceutical compositions according to claim 8, wherein said association is administered at doses ranging from 25 to 250 µg of triiodothyronine sulfate and from 25 to 200 µg of thyroxine.

15. (currently amended) Kit for the differential or sequential administration of the pharmaceutical compositions according to any one of claims 8, ~~9~~ and or 11 to 14.

16. (currently amended) Use of triiodothyronine sulfate for the preparation of the pharmaceutical compositions according to any one of claims 7, 8 or 10 to ~~15~~ 14.